HDAC6 score: to treat or not to treat?,Nature Cancer

当前位置： X-MOL 学术 › Nat. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

HDAC6 score: to treat or not to treat?
Nature Cancer ( IF 23.5 ) Pub Date : 2022-12-30 , DOI: 10.1038/s43018-022-00494-8
Joschka Hey _{1,

2,

3} , Maria Llamazares Prada _{1,

3} , Christoph Plass _{1,

2,

3}

Affiliation

Developing approaches to identify patients who may benefit from specific treatments is an important area of research. A study now defines an HDAC6 score to predict the response of patients with breast cancer to the HDAC6 inhibitor ricolinostat and characterizes its anti-tumor effects with preclinical mechanistic work and a phase 1b clinical trial.

中文翻译：